By Cocer Peptides 
15 days ago
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.
The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.
Growth Hormone (GH) plays a crucial role in numerous physiological processes, including growth, development, and metabolic regulation in living organisms. Its secretion is finely regulated by a complex neuroendocrine system, and Growth Hormone-Releasing Peptides (GHRPs) are a class of substances that stimulate growth hormone secretion, attracting significant attention from researchers. Ipamorelin, as a member of the GHRP family, stands out for its unique structure and pronounced ability to promote growth hormone secretion.
From a chemical structural perspective, Ipamorelin is a synthetic pentapeptide. This structure confers it with high affinity for the Growth Hormone-Releasing Peptide Receptor (GHRP-R), enabling it to effectively activate the receptor and initiate a series of intracellular signaling pathways, thereby promoting growth hormone secretion.
Compared to Growth Hormone-Releasing Hormone (GHRH), Ipamorelin offers several unique advantages. GHRH primarily acts on GHRH receptors on the surface of growth hormone cells in the anterior pituitary gland to stimulate the synthesis and release of growth hormone. Ipamorelin not only directly acts on the pituitary gland but also indirectly regulates growth hormone secretion by acting on the hypothalamus and other regions, offering a more diverse range of action pathways. Ipamorelin exhibits higher selectivity in promoting growth hormone secretion, exhibiting a more pronounced stimulatory effect on growth hormone secretion while having minimal impact on plasma levels of other pituitary hormones such as follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), and thyroid-stimulating hormone (TSH).
In animal experiments, Ipamorelin demonstrated excellent efficacy in promoting growth hormone secretion across various animal models, including rats, pigs, sheep, and dogs. In rat experiments, following administration of Ipamorelin, a rapid increase in plasma growth hormone levels was observed, exhibiting a dose-dependent relationship. This indicates that Ipamorelin can effectively regulate growth hormone secretion, providing robust experimental evidence for its potential applications in improving animal growth performance and treating related diseases.
Figure 1 Table 1 Structure–activity relations of some novel pentapeptides on GH release from rat pituitary cells in vitro – a comparison with GHRP-1, GHRP-2, GHRP-6, and GHRH. The results are shown as means ± SEM (n = 3–6 separate experiments).
Mechanism of action of Ipamorelin in promoting growth hormone secretion
Interaction with the growth hormone-releasing peptide receptor
The key initial step in Ipamorelin's role in promoting growth hormone secretion is its specific binding to the growth hormone-releasing peptide receptor (GHRP-R). GHRP-R belongs to the G protein-coupled receptor superfamily and is widely distributed in the anterior pituitary, the hypothalamus, and other peripheral tissues. The pentapeptide structure of Ipamorelin enables it to precisely interact with the ligand-binding pocket of GHRP-R, inducing a conformational change in the receptor. This conformational change acts as a “switch” to initiate intracellular signal transduction, allowing GHRP-R to interact with and activate downstream G proteins.
The activated GHRP-R promotes guanosine nucleotide exchange in the G protein α subunit coupled to it, with GDP being replaced by GTP, causing the G protein α subunit to dissociate from the G protein βγ dimer. The dissociated G protein α subunit and G protein βγ dimer can further activate different downstream signal transduction pathways, triggering a series of intracellular biological effects, ultimately leading to increased growth hormone secretion.
CJC-1295, as a synthetic growth hormone analog, aids in weight loss, muscle enhancement, skin rejuvenation, sleep improvement, and wound healing. Ipamorelin is a synthetic pentapeptide belonging to the class of growth hormone-releasing peptides (secretagogues). It stimulates the release of growth hormone and influences various physiological processes, including accelerating gastric emptying, improving postoperative intestinal obstruction symptoms, stimulating insulin secretion, and counteracting the catabolic effects of glucocorticoids on skeletal muscle and bone. Studying the synergistic effects of these two compounds could lead to new breakthroughs in health, sports medicine, and related disease treatments.
Figure 2 Plasma GH levels versus time in swine following i.v. administration of different doses of ipamorelin.
Activation of intracellular signal transduction pathways
Phospholipase C - protein kinase C pathway (PLC - PKC pathway): The activated G protein α subunit can activate phospholipase C (PLC), which hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP2) on the cell membrane into two important second messengers: inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses into the cytoplasm, binds to IP3 receptors on the endoplasmic reticulum, and promotes the release of calcium ions (Ca2+) from the endoplasmic reticulum, causing a rapid increase in intracellular Ca2+ concentration. DAG remains on the cell membrane and activating protein kinase C (PKC). PKC can regulate the expression of related genes by phosphorylating a series of downstream substrate proteins, such as transcription factors, thereby promoting the synthesis and secretion of growth hormone. The elevated intracellular Ca⊃2;⁺ concentration can also directly act on secretory vesicles to promote the release of growth hormone.
Mitogen-activated protein kinase pathway (MAPK pathway): In addition to the PLC-PKC pathway, Ipamorelin activates the mitogen-activated protein kinase pathway after activating GHRP-R to promote growth hormone secretion. The G protein βγ dimer activates the guanine nucleotide exchange factor (GEF), which promotes the conversion of GDP bound to Ras protein to GTP, thereby activating Ras protein. Activated Ras protein further activates Raf protein, which phosphorylates and activates the mitogen-activated protein kinase kinase (MEK). MEK is then phosphorylated and activates the extracellular signal-regulated kinase (ERK). After entering the cell nucleus, ERK phosphorylates a series of transcription factors, such as Elk-1, regulating the expression of genes related to growth hormone synthesis and secretion, thereby promoting the production and release of growth hormone.
Regulation of the hypothalamic-pituitary axis
The hypothalamic-pituitary axis plays a central role in the regulation of growth hormone secretion. Ipamorelin not only directly acts on growth hormone cells in the anterior pituitary gland to promote growth hormone secretion but also indirectly influences growth hormone release through regulation of the hypothalamus. GHRH and somatostatin (SST) secreted by the hypothalamus have promotional and inhibitory effects on growth hormone secretion, respectively. Ipamorelin can indirectly regulate growth hormone secretion by modulating the synthesis and release of GHRH and SST in hypothalamic neurons. Ipamorelin may inhibit the activity of SST neurons in the hypothalamus, reducing SST release, thereby alleviating the inhibitory effect of SST on growth hormone secretion. Ipamorelin can also enhance the excitability of GHRH neurons, promote GHRH release, and further stimulate growth hormone secretion. This dual regulatory effect on the hypothalamic-pituitary axis enables Ipamorelin to regulate growth hormone secretion levels.
The role of Ipamorelin in promoting growth hormone secretion
Promoting growth and development
During animal growth and development, growth hormone plays a key regulatory role, and Ipamorelin positively influences animal growth and development by promoting growth hormone secretion. In young animals, the use of Ipamorelin significantly increases growth rate. Taking rats as an example, after administering an appropriate dose of Ipamorelin, rats exhibit accelerated weight gain, enhanced proliferation and differentiation of skeletal growth plates, and increased long bone length. This can be attributed to the fact that growth hormone stimulates the production of insulin-like growth factor-1 (IGF-1) in tissues such as the liver. IGF-1 circulates through the bloodstream to tissues like bones, promoting the proliferation and differentiation of chondrocytes, thereby facilitating bone growth. Ipamorelin promotes growth hormone secretion, indirectly increasing IGF-1 production, thereby accelerating bone growth and development.
Ipamorelin also promotes muscle development. Growth hormone promotes protein synthesis, inhibits protein breakdown, and increases muscle mass. In animal experiments, after administering Ipamorelin, the animals exhibited thicker muscle fibers and enhanced muscle strength.
Regulatory effects on metabolism
Glucose metabolism regulation: Ipamorelin promotes growth hormone secretion, exerting a certain regulatory effect on glucose metabolism. Growth hormone has a dual role in glucose metabolism. At physiological levels, growth hormone stimulates insulin secretion, promotes glucose uptake and utilization, and lowers blood glucose levels. At high concentrations, growth hormone exhibits an anti-insulin effect, inhibiting peripheral tissue glucose uptake and utilization, thereby increasing blood glucose levels. Ipamorelin indirectly influences glucose metabolism balance by regulating growth hormone secretion. In normal animals, appropriate doses of Ipamorelin can maintain blood glucose at a relatively stable level, which can be attributed to its promotion of growth hormone secretion, which in turn stimulates insulin release to some extent, thereby regulating blood glucose. In diabetic animal models, the effects of Ipamorelin are more complex; it can improve insulin resistance by regulating growth hormone secretion, thereby exerting a positive influence on blood glucose control.
Fat metabolism regulation: Growth hormone promotes fat breakdown, increases fatty acid oxidation for energy production, and reduces fat accumulation. Ipamorelin promotes growth hormone secretion, thereby exerting its regulatory effect on fat metabolism. In animal experiments, after administering Ipamorelin, the fat content in the animals' bodies decreased, particularly in areas such as the abdomen. This is because growth hormone activates hormone-sensitive lipase (HSL) within fat cells, promoting the hydrolysis of triglycerides into fatty acids and glycerol. Fatty acids then enter mitochondria for β-oxidation to produce energy. Growth hormone also inhibits the differentiation of fat cells, reducing their number and further lowering body fat content. Ipamorelin, by promoting growth hormone secretion, plays a role in regulating fat metabolism and controlling body weight.
Effects on tissue repair and regeneration
Growth hormone plays a crucial role in tissue repair and regeneration. Ipamorelin, by promoting growth hormone secretion, provides favorable conditions for tissue repair and regeneration. In damaged tissues, growth hormone can stimulate cell proliferation and differentiation, promote the synthesis of extracellular matrix components such as collagen, and accelerate wound healing. In skin injury models, after using Ipamorelin, fibroblast proliferation at the wound site accelerates, collagen deposition increases, and wound healing time is shortened. This can be attributed to growth hormone promoting fibroblast secretion of cytokines such as transforming growth factor-β (TGF-β), which further stimulates fibroblast proliferation and collagen synthesis. Growth hormone also promotes the proliferation and migration of vascular endothelial cells, facilitating the formation of new blood vessels to provide adequate nutrition and oxygen to damaged tissues, thereby accelerating tissue repair. Ipamorelin's role in promoting tissue repair and regeneration makes it a promising candidate for potential applications in trauma treatment, plastic surgery, and other fields.
Applications of Ipamorelin in promoting growth hormone secretion
Potential applications in the medical field
Treatment of growth hormone deficiency: Growth hormone deficiency is a condition caused by insufficient growth hormone secretion, characterized by short stature and delayed growth and development. Compared to traditional growth hormone replacement therapy, Ipamorelin stimulates endogenous growth hormone secretion, avoiding some side effects associated with long-term use of exogenous growth hormone. Clinical studies have shown that in some patients with growth hormone deficiency, the use of Ipamorelin effectively increases growth hormone levels, accelerates height growth, and improves quality of life.
Anti-aging therapy: As people age, growth hormone secretion gradually decreases, which is closely related to many age-related physiological changes. Ipamorelin, which promotes growth hormone secretion, has a certain role in the field of anti-aging. By increasing growth hormone levels, Ipamorelin may improve body composition in the elderly, increase muscle mass, reduce fat accumulation, enhance bone density, and improve skin elasticity. Clinical trials have shown that elderly individuals who use Ipamorelin in appropriate doses experience improvements in physical function, stamina, and mental state.
Promoting wound healing: Ipamorelin promotes tissue repair and regeneration by stimulating growth hormone secretion. In medical practice, for patients with certain injuries, such as burns or fractures, using Ipamorelin can accelerate wound healing and reduce the occurrence of complications. In burn patients, Ipamorelin can promote epithelialization of the wound surface and reduce scar formation; in fracture patients, it can promote bone callus formation and accelerate fracture healing. This provides a new adjunctive treatment option for trauma management, with the potential to enhance treatment outcomes.
Applications in Sports Medicine
Due to its ability to stimulate growth hormone secretion, it can increase muscle mass, enhance athletic performance, and accelerate post-exercise recovery. In athletes engaged in high-intensity training, Ipamorelin may help them recover physical strength more quickly, reduce muscle fatigue, and minimize the risk of injury. In endurance athletes, Ipamorelin may enhance exercise endurance by promoting fat metabolism; in strength athletes, it can increase muscle strength and power.
Conclusion
In summary, as a pentapeptide that promotes growth hormone secretion, Ipamorelin demonstrates significant roles in growth and development, metabolic regulation, tissue repair, and various other application areas.
Sources
[1] Papak M. Ipamorelin - struktura i funkcija, 2016[C]. https://api.semanticscholar.org/CorpusID:78470780
[2] Adeghate E, Ponery A S, Emirates U A. O R I G I N A L A R T I C L E Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats, 2004[C]. https://api.semanticscholar.org/CorpusID:74621068
[3] Raun K, Hansen B S, Johansen N L, et al. Ipamorelin, the first selective growth hormone secretagogue.[J]. European Journal of Endocrinology, 1998,139 5:552-561.
Product available for research use only:
